Jump to content

Leukocyte apheresis: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Added link
BattyBot (talk | contribs)
General fixes, removed deadend tag using AWB (11769)
Line 1: Line 1:
{{Dead end|date=January 2016}}

'''Leukocyte apheresis''' is a medical device therapy (selective [[granulocyte]]/[[monocyte]] adsorptive {GMA} apheresis; GMDN<ref>{{Cite web|url = https://www.gmdnagency.com|title = Global Medical Device Network|date = |access-date = |website = |publisher = |last = |first = }}</ref> code: 47306) for the treatment of [[inflammation]] of the [[colon]]. It works by removing from the blood a group of [[white blood cells]] called activated [[leukocytes]]<ref>{{Cite journal|url = |title = The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review|last = Hanai H. et al|first = |date = January 2011|journal = Clinical & Experimental Immunology|doi = |pmid = |access-date = |edition = 163(1)|pages = 50–58}}</ref> that play a key role in the inflammatory stages of [[ulcerative colitis]] (UC).<ref>{{Cite journal|url = |title = Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation|last = Nikolaus S., Schreiber S. et al|first = |date = April 1998|journal = Gut|doi = |pmid = |access-date = |edition = 42(4)|pages = 470–476}}</ref> Selectively reducing these cells in the blood helps to reduce inflammation in the colon.<ref>{{Cite journal|url = |title = Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.|last = Muratov V. et al|first = |date = 2008|journal = Journal of Gastroenterology|doi = |pmid = |access-date = |issue = 43|pages = 277–282}}</ref> Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.<ref>{{Cite web|url = https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p511-efficacy-and-safety-of-granulocytemonocyte-adsorptive-apheresis-in-steroid-dependent-active-ulcerative-colitis-with-insufficient-response-or-intolerance-to-immunosuppressants-andor-biological-therapies-the-art-trial-results-at-24-and-48-weeks.html?highlight=YToxOntpOjA7czo5OiJhZGFjb2x1bW4iO30|title = P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks|date = 2015|access-date = |website = ecco-ibd.eu|publisher = The European Crohn's and Colitis Organisation (ECCO)|last = Dignass A. et al|first = }}</ref>
'''Leukocyte apheresis''' is a medical device therapy (selective [[granulocyte]]/[[monocyte]] adsorptive {GMA} apheresis; GMDN<ref>{{Cite web|url = https://www.gmdnagency.com|title = Global Medical Device Network|date = |access-date = |website = |publisher = |last = |first = }}</ref> code: 47306) for the treatment of [[inflammation]] of the [[colon]]. It works by removing from the blood a group of [[white blood cells]] called activated [[leukocytes]]<ref>{{Cite journal|url = |title = The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review|last = Hanai H. et al|first = |date = January 2011|journal = Clinical & Experimental Immunology|doi = |pmid = |access-date = |edition = 163(1)|pages = 50–58}}</ref> that play a key role in the inflammatory stages of [[ulcerative colitis]] (UC).<ref>{{Cite journal|url = |title = Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation|last = Nikolaus S., Schreiber S. et al|first = |date = April 1998|journal = Gut|doi = |pmid = |access-date = |edition = 42(4)|pages = 470–476}}</ref> Selectively reducing these cells in the blood helps to reduce inflammation in the colon.<ref>{{Cite journal|url = |title = Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.|last = Muratov V. et al|first = |date = 2008|journal = Journal of Gastroenterology|doi = |pmid = |access-date = |issue = 43|pages = 277–282}}</ref> Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.<ref>{{Cite web|url = https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p511-efficacy-and-safety-of-granulocytemonocyte-adsorptive-apheresis-in-steroid-dependent-active-ulcerative-colitis-with-insufficient-response-or-intolerance-to-immunosuppressants-andor-biological-therapies-the-art-trial-results-at-24-and-48-weeks.html?highlight=YToxOntpOjA7czo5OiJhZGFjb2x1bW4iO30|title = P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks|date = 2015|access-date = |website = ecco-ibd.eu|publisher = The European Crohn's and Colitis Organisation (ECCO)|last = Dignass A. et al|first = }}</ref>


Line 6: Line 4:
{{Reflist}}
{{Reflist}}


{{Uncategorized|date=January 2016}}


{{Uncategorized stub|date=January 2016}}
{{stub}}
{{stub}}

Revision as of 00:57, 23 January 2016

Leukocyte apheresis is a medical device therapy (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) for the treatment of inflammation of the colon. It works by removing from the blood a group of white blood cells called activated leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]

References

  1. ^ "Global Medical Device Network".
  2. ^ Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology (163(1) ed.): 50–58. {{cite journal}}: Explicit use of et al. in: |last= (help)
  3. ^ Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut (42(4) ed.): 470–476. {{cite journal}}: Explicit use of et al. in: |last= (help)
  4. ^ Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology (43): 277–282. {{cite journal}}: Explicit use of et al. in: |last= (help)
  5. ^ Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO). {{cite web}}: Explicit use of et al. in: |last= (help)